RESUMO
OBJECTIVES: To provide an overview of key issues and resources related to complementary and alternative medical (CAM) and integrative approaches in cancer care. DATA SOURCES: Peer-reviewed publications and web sites of professional, federal, and academic institutions and organizations. CONCLUSION: The field of integrative oncology is growing and research evidence in this area is burgeoning. Many cancer patients are using and can benefit from CAM. There are many resources and educational opportunities available to oncology nurses to enhance their CAM knowledge and skills. IMPLICATIONS FOR NURSING PRACTICE: Nurses must keep abreast of the growing evidence in integrative oncology that documents the safety and efficacy of different CAM approaches for cancer patients. It is critical that nurses be aware of reputable resources and legal implications related to use of CAM.
Assuntos
Terapias Complementares/enfermagem , Neoplasias/enfermagem , Enfermeiras e Enfermeiros , Enfermagem Oncológica/tendências , Competência Clínica , Terapias Complementares/tendências , Conhecimentos, Atitudes e Prática em Saúde , Enfermagem Holística , HumanosRESUMO
The terms "alternative" or "unconventional" have been used to describe any therapy used instead of conventional approaches. Conventional approaches, known as "standard" or "traditional" or "biomedical" approaches, have had broad application in Western medicine. Complementary and alternative medicine has been referred to as "integrative," "integrated," or "complementary" when therapies are combined with conventional approaches, such as those for cancer.
Assuntos
Terapias Complementares , Neoplasias/terapia , Medicina Baseada em Evidências , HumanosAssuntos
Intercâmbio Educacional Internacional , Enfermagem Oncológica , Croácia , Humanos , Papel do Profissional de Enfermagem , Enfermagem Oncológica/educação , Enfermagem Oncológica/organização & administração , Autonomia Profissional , Competência Profissional , Sociedades de Enfermagem/organização & administraçãoAssuntos
American Medical Association , Licenciamento em Enfermagem/legislação & jurisprudência , Manobras Políticas , Papel do Profissional de Enfermagem , Enfermagem Oncológica/legislação & jurisprudência , Prática Profissional/legislação & jurisprudência , Humanos , Sociedades de Enfermagem , Estados UnidosAssuntos
Diversidade Cultural , Neoplasias , Enfermagem Oncológica/organização & administração , Enfermagem Transcultural/organização & administração , Atitude Frente a Saúde/etnologia , Competência Clínica , Humanos , Neoplasias/etnologia , Neoplasias/enfermagem , Guias de Prática Clínica como Assunto , Sociedades de Enfermagem/organização & administração , Estados UnidosAssuntos
Licenciamento em Enfermagem/legislação & jurisprudência , Papel do Profissional de Enfermagem , Autonomia Profissional , American Medical Association , Humanos , Manobras Políticas , Enfermagem Oncológica/organização & administração , Sociedades de Enfermagem/organização & administração , Estados UnidosRESUMO
Healthcare providers believe they have a positive impact on controlling chemotherapy-induced nausea and vomiting (CINV), yet patients still consider CINV to be one of the most distressing side effects of chemotherapy. The effect of CINV on daily activities has been measured using the Functional Living Index-Emesis (FLIE) scale, a validated, nausea- and vomiting-specific, patient-reported outcome instrument comprising nine items in each of two domains. This research explores the potential correlation between reducing CINV and improved quality of life. In clinical trials, patients completed the FLIE questionnaires 24 and 96 hours after receiving moderately emetogenic chemotherapy and antiemetic therapy using a serotonin receptor antagonist (ondansetron, dolasetron, or palonosetron). Significantly more patients given palonosetron had FLIE scores that reflected lessened impact of nausea on daily life during the acute period (0-24 hours) and of nausea/vomiting during both the acute and delayed periods (days 2-4). These findings strongly suggest that better antiemetic prevention allows patients to maintain their functional status for up to 5 days after chemotherapy.
Assuntos
Atividades Cotidianas , Antieméticos/uso terapêutico , Antineoplásicos/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Qualidade de Vida , Receptores 5-HT3 de Serotonina/uso terapêutico , Vômito/induzido quimicamente , Adulto , Idoso , Neoplasias da Mama/tratamento farmacológico , Feminino , Humanos , Neoplasias Pulmonares/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Náusea/induzido quimicamente , Náusea/tratamento farmacológico , Antagonistas do Receptor 5-HT3 de Serotonina , Inquéritos e Questionários , Vômito/tratamento farmacológicoAssuntos
Antineoplásicos/efeitos adversos , Tinturas para Cabelo/efeitos adversos , Educação de Pacientes como Assunto , Neoplasias da Mama/induzido quimicamente , Neoplasias da Mama/epidemiologia , Humanos , Papel do Profissional de Enfermagem , Enfermagem Oncológica/métodos , Fatores de Risco , Neoplasias da Bexiga Urinária/induzido quimicamente , Neoplasias da Bexiga Urinária/epidemiologiaRESUMO
Glutamine is a nonessential amino acid contained in most dietary proteins and provides immune functions and fuel for the small intestine. For healthy people, dietary glutamine (from protein) usually is considered adequate. Results of research evaluating the potential benefits of glutamine during cancer therapy are encouraging but remain inconclusive. Some researchers have suggested recently that glutamine may, in fact, be a conditionally essential amino acid (Buchman, 2001). Decreases in glutamine levels after trauma or major burns, postoperatively, and in patients with diseases such as inflammatory bowel disease, AIDS, and cancer are widely recognized and acknowledged (Medina, 2001; Miller, 1999). The interpretation of data suggesting that glutamine supplementation is of benefit in almost any clinical situation is controversial. Additional research is needed to confirm the mechanism of action and efficacy of glutamine as adjuvant therapy in patients receiving cancer treatment.